65,437 trials
Stage IV Non-small Cell Lung Cancer (NSCLC) · Recurrent Non-small Cell Lung Cancer (NSCLC) · Extensive-stage Small Cell Lung Cancer (SCLC)
Primary: Central Nervous System (CNS) Disease Control Rate (Cohort A and C) — 2; 2 Participants
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
Breast Cancer
Primary: Rate of Breast Related Adverse Events — 12 Reconstructed breasts affected
Ankylosing Spondylitis
Primary: Assessment of SpondyloArthritis International Society 20 Response (ASAS20) — 21 participants
Healthy Participants
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 4; 2; 2; 3 participants
Cognitive Impairment
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 51.89; 45.90; 48.37 T-scores — p=0.003
Hypercholesterolemia · Acute Coronary Syndrome
Primary: Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36 — -3.14; -4.79 percent change — p=0.2279
HIV/AIDS
Primary: Adherence Rate — 20; 17 Participants — p=0.29
Colorectal Neoplasm · Colorectal Cancer
Primary: Number of Patients With Adverse Events — 5; 0 Participants
Ischemic Stroke
Primary: Early Arrival After Stroke Onset — 0.5 change in percent early arrival/month — p=<.0001
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530
Advanced Non-hematologic Malignancies
Primary: Part 1: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Plasma Cell Myeloma
Primary: Total Daratumumab Infusion Time — 1.5 hours
Phantom Limb Pain
Primary: Phantom Limb Pain Questionnaire (PLPQ) — 1.2; .5 units on a scale